Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mitotane
Drug ID BADD_D01479
Description A derivative of the insecticide dichlorodiphenyldichloroethane that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
Indications and Usage For treatment of inoperable adrenocortical tumours; Cushing's syndrome
Marketing Status approved
ATC Code L01XX23
DrugBank ID DB00648
KEGG ID D00420
MeSH ID D008939
PubChem ID 4211
TTD Drug ID D0Z5OE
NDC Product Code 71052-048; 76336-080; 62991-2604; 14799-2009; 38779-2263; 21222-002; 49452-4786
UNII 78E4J5IB5J
Synonyms Mitotane | o,p-DDD | Mytotan | ortho,para-DDD | ortho,para DDD | Chlodithane | Lysodren | Chloditan | Khloditan
Chemical Information
Molecular Formula C14H10Cl4
CAS Registry Number 53-19-0
SMILES C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mental disability26.01.01.001--Not Available
Movement disorder17.01.02.010--Not Available
Mucosal inflammation08.01.06.002--Not Available
Muscular weakness15.05.06.001; 17.05.03.005--
Nausea07.01.07.0010.000336%
Neoplasm16.16.02.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Neurotoxicity17.02.10.002; 12.03.01.0110.000336%Not Available
Neutropenia01.02.03.0040.000112%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Osteoarthritis15.01.04.001--Not Available
Ovarian cyst21.11.01.002; 16.04.03.0010.000470%Not Available
Pain08.01.08.004--
Pancreatitis acute07.18.01.0020.000112%Not Available
Paraesthesia23.03.03.094; 17.02.06.0050.000112%
Pleural effusion22.05.02.0020.000112%
Polyneuropathy17.09.03.012--Not Available
Protein bound iodine decreased13.10.06.003--Not Available
Proteinuria20.02.01.011--
Rash23.03.13.001--Not Available
Retinal disorder06.08.03.005--Not Available
Retinopathy24.03.07.003; 06.10.02.001--
Salivary hypersecretion07.06.01.009--Not Available
Secondary adrenocortical insufficiency14.11.01.014; 05.03.04.012--Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.0060.000168%
Speech disorder17.02.08.003; 22.12.03.027; 19.19.02.002--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tremor17.01.06.002--
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages